

Tracleer® (bosentan) – New formulation approval

- On September 6, 2017, <u>Actelion announced</u> the FDA approval of <u>Tracleer (bosentan)</u> tablet for oral suspension, to support a new indication for the treatment of pulmonary arterial hypertension (PAH) [WHO Group I] in pediatric patients ≥ 3 years old with idiopathic or congenital PAH to improve pulmonary vascular resistance, which is expected to result in an improvement in exercise ability.
 - Tracleer is also available as 62.5 mg and 125 mg film-coated oral tablets.
- Tracleer is also indicated for the treatment of PAH in adults to improve exercise ability and to decrease clinical worsening.
 - Studies establishing effectiveness included predominantly patients with WHO Functional Class II – IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%).
- The new indication for Tracleer was approved based on an open-label, uncontrolled study in 19 pediatric patients (3 15 years old) with PAH.
 - In this study, cardiopulmonary hemodynamic improvements were similar to those seen in adults treated with Tracleer.
 - In addition, the safety of Tracleer in pediatric patients is supported by data from 100 pediatric patients treated with Tracleer for a median of 17 months.
- Tracleer carries a boxed warning regarding the risk of hepatotoxicity and embryo-fetal toxicity.
- The recommended dosage of Tracleer is as follows:

Population	Initial 4 weeks	Maintenance (after 4 weeks)
Patients > 12 years old and > 40 kg	62.5 mg orally twice daily	125 mg orally twice daily
Patients > 12 years old and < 40 kg	62.5 mg orally twice daily	62.5 mg orally twice daily
Patients ≤ 12 years old and ≥ 4 – 8 kg	16 mg orally twice daily	16 mg orally twice daily
Patients ≤ 12 years old and > 8 – 16 kg	32 mg orally twice daily	32 mg orally twice daily
Patients ≤ 12 years old and > 16 – 24 kg	48 mg orally twice daily	48 mg orally twice daily
Patients ≤ 12 years old and > 24 – 40 kg	64 mg orally twice daily	64 mg orally twice daily

- Tracleer tablets for oral suspension should be dispersed in a minimal amount of water immediately before administration.
- Actelion plans to launch the new formulation of Tracleer in the 4th quarter of 2017. The new formulation will be available as a 32 mg tablet for oral suspension.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.